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Abstract
Complexes of zinc with picolinic and aspartic acids inhibit key steps of HSV-1 replication affecting different
virus-specific targets. As was recently demonstrated by us, the pavine alkaloid (-)-thalimonine irreversibly
inhibits HSV-1 infection in cultured cells. The aim of the present study was the evaluation of the combined
effect of zinc complexes and (-)-thalimonine on uninfected and HSV-1 infected cells. The data obtained have
shown that zinc complexes and the alkaloid exert decreased cytotoxicity (antagonistic effect) and
significantly increased anti-HSV-1 activity (synergistic effect) when applied in dual chess-board
combinations as compared to the individual effects of compounds tested. These combinations are also
effective against the infection caused by a resistant to acyclovir (ACV) HSV-1 mutant and the effect has been
recognised as synergistic.
Introduction
Our previous data have shown that complexes of zinc with picolinic and aspartic
acids Zn(pic)2 and Zn(asp)2, inhibit key steps ofHSV-1 replication altering: ( i) the synthesis of essential
viral regulatory proteins (ICP4, ICPS) and of structural glycoproteins (gD, gH) and, (ii) the morphogenesis of
infectious viral progeny (1, 2).
Furthermore, the pavine alkaloid (-)-thalimonine, isolated from Thalictrum simplex (L.), negatively affects
HSV-1 infection in cultured cells as was already demonstrated by us (3).
However, it is well known that during the systemic administration of antivirals, resistant HSV mutants appear
with high frequency (4, 5). This problem could be solved by combination therapy using compounds which
affect different virus-specific targets. That is why we decided to investigate whether it is possible to increase
the effect of zinc complexes against HSV-1 infection when applied in combination with the alkaloid. A
special attention was paid on the effectiveness of the combinations against the infection caused by a resistant
to ACV HSV-1 mutant.
Materials and Methods
1. Cells and viruses. Continuous Madine Darbey bovine kidney (MDBK) cells were grown in RPMI 1640
medium (GIBCO BRL) supplemented with 10% bovine serum (BS) and antibiotics. The same medium
supplemented with 5% BS and antibiotics was used in the antiviral experiments. Two HSV-1 strains were
used: the first one, Victoria, is sensitive to ACV, while the second one, R-100 (ACVR, TKA), is resistant due
to a mutation in the viral gene encoding the enzyme thymidine kinase (TK). Viral stocks were prepared by
infecting MDBK cells, harvesting at a full cytopathic effect (CPE), freezing and thawing three times and then
stored at-70C.
2. Compounds tested. Zinc complexes with picolinic and with aspartic acids Zn(pic)2 and Zn(asp)2, and the
pavine alkaloid (-)-3,4-methylenedioxy-2,8,9-trimethoxypavinane, further designated as
(-)-thalimonine, isolated from the aerial parts ofthe mongolian plant Thalictrum simplex (L.),
Ranunculaceae, were used in the combinatory experiments.
3. Single-cycle growth experiments. MDBK cells from confluent monolayers were infected with
HSV-1, strain Victoria. After lh for attachment cells were covered with media modified with 10 tM of the
appropriate compound. At the 2h, 4h, 8h, 10h, 12h and 15h samples were freezed, thawed and titrated in 96-
well microplates.The data were compared with the viral controls infected cells cultured in unmodified
medium and collected at the same intervals. The infectiuos viral titres were expressed as lOgl0 of infectious
units (i.u.) per 0.1ml and as a per cent from the viral control.
4. Combinatory assays.
4.1. Cytotoxicity assay. Confluent monolayers from MBDK cells grown in 96-well plates were covered with
medium supplemented with compounds tested, either alone or in dual combination. The cytotoxicity was
evaluated on the 48h, 72h and 96h after culturing cells at 37C by trypan blue exclusion tesl. Cells covered
with unmodified, compound-free medium and cultured in the same experimental conditions served as a
control. The concentration which reduced the cell survival rate with 50% as compared to the untreated
control was designated as 50% cytotoxic (CC50).
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4.2. Antiviral assay. Confluent monolayers were infected with the appropriate HSV-1 strain in ten-fold
dilutions. Ater h for adsorption cells were covered with medium modified with the compounds tested,
either alone or in dual combinations. The infectious viral titres were determined on the 48h or 72h after
infection with strain Victoria or R-100, respectively. The anti-HSV-1 activity was expressed as a reduction of
the viral titres as compared to the control infected cells covered with unmodified medium. The
concentration required to reduce the infectious viral titre with 50% was designated as 50% inhibitory (IC5o).
Data from the combinatory assays were estimated by the three-dimensional model of Prichard and Shipman
(6). According to this model, synergistic or antagonistic effects can be identified using dual chess-board
combinations of compounds applied in the following concentrations: 2CC50, CC0, CC50/2, CC50/4, CC50/8 or:
2IC5o, IC5o, IC5o/2, IC5o/4 and IC5018. Based on the experimentally observed results from toxicity and antiviral
experiments, the theoretical additive effect was calculated and subtracted from the observed effect. The data
after subtraction were presented graphically where values below 0 were indicative for antagonostic effect,
while those above 0 for synergistic effect.
Results and discussion
Single-cycle growth tests are useful for characterisation of viral replication specificities. These tests are also
informative when the target period during which the particular compound specifically suppresses viral
replication, has to be identified. As is shown in fig. 1, the compounds tested affect HSV-1 infection in a
different manner when evaluated in single-cycle growth conditions.
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Thus, Zn(pic)2 and Zn(asp)2 negatively affect the whole period of HSV-I replication suppressing the
expression of immediate early (IE), early (E) and late (L) gene products. These results confirm the data
previously reported by us (1, 2). Using monoclonal antibodies, immunoblotting and electron microscopy it
was shown that Zn(pic)2 and Zn(asp)2 inhibit essential regulatory and structural HSV-1 proteins (1, 2) and the
morphogenesis of viral progeny (1). However, the peak of activity of Zn(pic)2 has been measured on the 8h
post infection, respectively 7h after the treatment and, at the end of the replication cycle 10% of infectious
viral progeny is produced. As concern Zn(asp)2, its suppressive activity progressively increases with the
prolongation of action and on the 15h 0.6% of infectious viral progeny is only produced. Contrary, the
alkaloid (-)-thalimonine affects the early period of HSV-1 replication, as the amount of infectious viral
progeny is reduced between the 4h and 10h ater the infection, respectively 3h 9h after the treatment. Till
the end of the replicative cycle (-)-thalimonine is uneffective, as demonstrated by the restored viral infectivity
on the 12h and 15h, reaching control level (fig. 1).
The fact that zinc complexes and (-)-thalimonine affect different periods of HSV-I replication motivated us
to use these compounds in dual combinatory experiments.
In the first set of experiments individual CC50 values of compounds tested were evaluated. The respective
CC5o are 100 laM for both zinc complexes and 30 laM for (-)-thalimonine. In the next set of experiments,
based on the individual CC50, the cytotoxicity ofcombinations was evaluated (tables and 2, fig. 2 and 3).
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Tableotoxic effect ofZn-thalimonine applied alone and in combination *
Zn(pic)2
2CC5o
CC5o
CC5o/2
CC5o/4
CC5o/8
0
CC5o/8
’-)-thalimonine
cC,o/4 CC5o t 2CC5o
25 23.5 21 18 14.5 11
50 35 30 24.5 19 15
60 55 37 28 20 18.5
71 60 51 30 25
62 70
35
55.5 75
77
45
75 62 50
* data shown in per cent ofthe cell control; cell control; 100 laM; * 30
30
35
Table 2. Observed cytotoxic effect ofZn(asp)2 and (-)-thalimonine applied alone and in combination *
(-)-thalimonine
Zn(asp)2 0 CC5o/8 CC5o/4 CC5o/2 CC5o t 2CC5o
2CC50 30 25 20 18 15.5
CC5o 50 30 25.5 15.5 11 10
CC5o/2 60 5’1.5 48 32 27.5 20
CC5o/4 75 62 58.5 53 46
...CC50/8 82 71 66.6 59.5 49
0 100 75 70 63 50 38
data shown in per cent ofthe cell control; cell control; i’00 laM; * 30 M
10
35
37
-10
Fig. 2 Combined cytotoxic effect ofZn(pic)2 and
(-)-thalimonine
-70
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The data demonstrate that when the appropriate zinc complex is simultaneously applied with (-)-thalimonine,
the observed cytotoxic effect is antagonistic, i.e. the compounds neutralize their cytotoxicity when used in
combination. This is manifested by the decreased cytotoxicity of combinations as compared to that of
compounds applied alone. Thus, the cytotoxicity of the combination Zn(pic)2 and (-)-thalimonine is up to
54% lower (table 1, fig. 2), while that of combination Zn(asp)2 and (-)-thalimonine is up to 50% lower than
that obtained under the single action ofcompounds tested (table 2. fig. 3).
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Fig. 3 Combined cytotoxic effect ofZn(asp) 2 and
(-)-thalimonine
0250/4 0250/8 0
(-)-thalimonine, uM
The antagonistic cytotoxic effect expressed by combinations used encouraged us to continue our experiments
in order to identify the dual effect of zinc complexes and (-)-thalimonine on HSV-1 infection in the same cell
culture system. The antiviral efficacy of combinations was compared to that after single application of the
particular compound.
The experimental data on the combined effect of Zn(pic)2 and (-)-thalimonine against strain Victoria show
that the inhibitory effect is increased as compared to that of Zn(pic)2 and (-)-thalimonine applied alone (table
3, fig. 4). According to the method of Prichard and Shipman, the antiviral effect of the combination can be
defined as synergistic. The synergism is most pronounced when IC50/2 Zn(pic)2 is combined with IC50/2 (-)-
thalimonine (fig. 4).
Fig. 4 Combined effect ofZn(pic) 2 and (-)-thalimonine
on the replication ofHSV-lsaail Victoria
(-)-thalimonine, uM
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Table 3. Combined effect ofZn(pic)2 and (-)-thalimonine on the replication ofHSV-1 strain Victoria *
(-)’thalimonine
0
ICso
IC5o/8 ICso/4 IC5o/2 Zn(pic)2,
2IC5o 68 75 80 ,83.4 90
50 80 83.4 83.4
IC5o/2
75
27
27
IC5o/4
68
50
27 75
68 27
80
75
IC5o/8 0 27 50
0 100 0 27 27 68
data shown in per cent inhibition as compared to the viral control; viral control:
4.33 logo i.u./0.1 ml; 10 taM; * 0.001 taM
2IC5o
96.5
90
80
80
75
75
infectious viral titre
The effect of combination of Zn(asp)2 and (-)-thalimonine against the infection caused by strain Victoria is
also synergistic (table 4, fig. 5). The synergism is most pronounced when IC5o/4 Zn(asp)2 is combined with
IC5o/2 of(-)-thalimonine (fig. 5).
Fig.5 Combined effect ofZn(asp) 2 and (-)-thalimonine
on the replication ofHSV-lstmin Victoria
21C50 IC50 IC50/2 IC50/4 0
IC50/8
0
(-)-thalimonine, uM
IC5O
2IC50
IC50/8
IC50/4
IC50/2
Zn(asp)2, uM
Table 4. Combined effect ofZn(asp)2 and (-)-thalimonine on the replication ofHSV-1 strain Victoria *
(-)-thalimonine
Zn(asp)2
2IC5o
IC50
IC5o/2
0
50
IC5o/8
75
68
IC5o/4
80
75
IC5o/2
83.4
80
2IC50
96.5
94
27 50 68 75 80 92
IC4 0 27 50 68 75 90
IC58 0 27 27 50 68 83.4
0 100 0 27 27 68 75
* data shown in per cent inhibition as compared to the viral control; viral control; infectious viral titre 4.33
logoi.u./0.1ml; 25 taM; 0.001 [aM
The experimental data showing the synergistic effect ofcombinations against the infection caused by the
resistant to ACV strain R-100 represent significant interest (tables 5 and 6). The combination of IC50/4
(-)-thalimonine and IC5o/2 Zn(pic)2 or Zn(asp)2 is the most effective (fig. 6 and 7). However, it has to be
noted that when applied in low concentrations, such as IC50/8, the combination of zinc complexes and
(-)-thalimonine still exert a significant synergistic activity against ACV resistant strain R-100.
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Table 5. Combined effect ofZn(pic)2 and (-)-thalimonine on the replication ofHSV-1 strain R-100
(ACVR’ TKA) *
(-)-thalimonine
Zn(pic)2
2IC5o
IC50
ICo/,2
0
50
27
IC5d8
68
68
IC5o/4
80
68
90
80
ICed2
50 50 75
IC5o/4 27 27 50 68
IC5o/8 27 27 68 0
100
83.4
75
68
50
27 50
2IC0
94
83.4
83.4
75
75
68
* data shown in per cent inhibition as compared to the viral control; viral control; infectious viral titre 4.31
log0 i.u./0.1ml; 20 laM; 0.0000001 laM
Fig. 6 Combined effect ofZn(pic) 2 and (-)-thalimonine
on the replication HSV-lstmin R-100
(-)-thalimonine, uM
ic)2, uM
Table 6. Combined effect ofZn(asp)2 and (-)-thalimonine on the replication ofHSV-1 strain R-100
(ACVR, TKA) *
Zn(asp)2
2IC5o 68 !C5o/8
75
(-)stha!imonine
ICo/4
80 83.4
IC5o
94
’2IC5o
96.8
ICso 50 68 75 83A 90 94
icsd2 27 50 68 83.4 90 92
ICsd4 27 27 50 68 75 80
ICsd8 0 27 27 50 68 75
0 ’100 0 0 27 50 68
* data shown in per Cent inhibition as compared to the viral control; viral control; infectious viral titre 4.33
lOglo i.u./O.lml; 30 laM; 0.0000001 M
262Metal BasedDrugs Vol. 7, Nr. 5, 2000
Fig. 7 Combined effect ofZn(asp) and (-)-thalimonine
on the replication ofHSV-1 strain R-100
::::i :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Zn(asp)2, uM
21C50
IC50 IC50/2 IC50/4
IC50/8 0
(-)-thalimonine, uM
In summary, the data obtained demonstrate that the effect of dual combinations of zinc complexes and the
pavine alkaloid (-)-thalimonine depends on the target cells specificity, i.e. when cells are uninfected the effect
is antagonistic,while in HSV-1 infected cells the effect is synergistic.
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